MIVOLIS Sweetener Tablets 2400 pcs. - Table Sweeteners | Germany

Product Information

O atenţie deosebită trebuie acordată pacienţilor care prezintă evenimente adverse cutaneo-mucoase; în acest caz trebuie avută în vedere întreruperea tratamentului cu Movalis. Combination use of ACE inhibitors or angiotensin receptor antagonists, anti-inflammatory drugs and thiazide diuretics. The use of an ACE inhibiting drug (ACE inhibitor or angiotensin receptor antagonist), an anti-inflammatory drug (NSAID or COX-2 inhibitor) and a thiazide diuretic at the same time increases the risk of renal impairment. This includes use in fixed combination products containing more than one class of drug. Combined use of these medications should be accompanied by increased monitoring of serum creatinine, particularly at the institution of the combination. The combination of drugs from these three classes should be used with caution particularly in elderly patients or those with pre-existing renal impairment. Higher doses of Movalis (22.5 mg and greater) have been associated with an increased risk of serious gastrointestinal tract (GIT) adverse events, therefore, the daily dose of Movalis should not exceed 15 mg.

Concomitant administration of a potentially myelotoxic drug, in particular methotrexate, appears to be a predisposing factor to the onset of a cytopenia. AINS inhibă sinteza renală a prostaglandinelor care menţin perfuzia renală. Administrarea AINS la pacienţii cu flux şi volum sanguin renal reduse poate favoriza instalarea decompensării funcţiei renale, care de obicei se remite după întreruperea tratamentului cu AINS. Oral hypoglycaemics. Interactions via CYP 2C9 can be expected in combination with medicinal products such as oral anti-diabetics (sulfonylureas), which may lead to increased plasma levels of these drugs and meloxicam. Patients concomitantly using meloxicam with sulfonylureas should be carefully monitored for hypoglycemia. Caution should be exercised when treating patients with a history of upper gastrointestinal disease and in patients receiving treatment with anticoagulants. Patients with GI symptoms should be monitored. Movalis therapy should cease if peptic ulceration or GI ulceration or bleeding occurs.

What is in this leaflet

daca sunteti alergic (hipersensibil) la acid acetilsalicilic sau la alte medicamente antiinflamatoare nesteriodiene (AINS); daca dupa un tratament anterior cu AINS sau daca ati avut recent sangerari la nivelul stomacului sau intestinului, perforatii la nivelul stomacului sau intestinului, ulcer sau sangerari la nivelul stomacului sau intestinului corticosteroids (drugs usually used to treat inflammatory conditions, such as skin rash and asthma) MOVALIS is used to treat the symptoms of osteoarthritis. This disease mainly affect the joints causing pain and swelling. Genotoxicity. Meloxicam did not demonstrate genotoxic potential in assays for gene mutation in vitro and chromosomal damage in vitro and in vivo.

If it is almost time for your next dose (e.g. within 2-3 hours), skip the dose you missed and take your next dose when you are meant to. Chemical names: 4-hydroxy-2-methyl -N-(5-methyl-2- thiazolyl)-2 H-1,2-benzothiazine-3- carboxamide-1,1-dioxide and 2 H-1,2-benzothiazine-3- carboxamide, 4-hydroxy-2-methy -N-(5-methyl-2-thiazolyl)-1,1-dioxide. Molecular formula: C 14H 13N 3O 4S 2. MW: 351.4. CAS: 71125-38-7. Meloxicam is a pastel yellow solid with pKa values of 1.09 and 4.18 and a melting point of about 256°C. The substance is practically insoluble in water, soluble in dimethylformamide, slightly soluble in chloroform and acetone and very slightly soluble in methanol. There are no chiral centres and no polymorphs are formed under normal conditions. Perioperative treatment of pain in patients undergoing coronary artery bypass graft surgery (CABG). veziculatie severa a pielii sau descuamarea pielii (sindrom Steven-Johnson sau necroliza epidermica toxica)

La pacienţii cu insuficienţă renală în stadiul terminal hemodializaţi, doza de Movalis nu trebuie să depăşească 7,5 mg pe zi. La pacienţii cu insuficienţă renală uşoară sau medie nu este necesară reducerea dozei (de exemplu, la pacienţii cu clearance al creatininei mai mare de 25 ml/min). Hipersensibilitate la meloxicam sau orice excipient al medicamentului. Este posibila sensibilitatea incrucisata cu acidul acetilsalicilic sau cu alte ains. Movalis nu trebuie administrat pacientilor care prezinta semne de astm, polipi nazali, angioedem sau urticarie, urmare a administrarii de acid acetilsalicilic sau alt antiinflamator; in caz de ulcer peptic activ, insuficienta hepatica severa, insuficienta renala severa nedializata, copii si adolescentii sub 15 ani, sarcina sau alaptare.

Some of the symptoms of an allergic reaction may include skin rash, itching or hives, swelling of the face, lips, tongue or other parts of the body, shortness of breath, wheezing or troubled breathing. NSAIDs should be prescribed with caution in patients with a prior history of recent ulcer disease or GI bleeding. Nefrotoxicitatea ciclosporinei poate fi crescută de AINS prin efecte mediate de prostaglandinele renale. Se va monitoriza funcţia renală pe parcursul tratamentului asociat. Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome, and toxic epidermal necrolysis, have been reported very rarely in association with the use of NSAIDSs (see 4.8). Patients appear to be at highest risk for these reactions early in the course of therapy: The onset of the reaction occurring in the majority of cases within the first month of treatment. Movalis should be discontinued at the first appearance of skin rash, mucosal lesions, or any other sign of hypersensitivity.Exacerbations of Osteoarthritis: 7.5 mg/day (half a 15 mg tablet); if necessary, in the absence of improvement, the dose may be increased to 15 mg/day.